184 related articles for article (PubMed ID: 14871847)
21. The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.
Siakavellas SI; Sfikakis PP; Bamias G
Semin Arthritis Rheum; 2015 Aug; 45(1):1-8. PubMed ID: 25887448
[TBL] [Abstract][Full Text] [Related]
22. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.
Bamias G; Siakavellas SI; Stamatelopoulos KS; Chryssochoou E; Papamichael C; Sfikakis PP
Clin Immunol; 2008 Nov; 129(2):249-55. PubMed ID: 18757243
[TBL] [Abstract][Full Text] [Related]
23. Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3.
Hsu MJ; Lin WW; Tsao WC; Chang YC; Hsu TL; Chiu AW; Chio CC; Hsieh SL
Exp Cell Res; 2004 Jan; 292(2):241-51. PubMed ID: 14697332
[TBL] [Abstract][Full Text] [Related]
24. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.
Wroblewski VJ; Witcher DR; Becker GW; Davis KA; Dou S; Micanovic R; Newton CM; Noblitt TW; Richardson JM; Song HY; Hale JE
Biochem Pharmacol; 2003 Feb; 65(4):657-67. PubMed ID: 12566095
[TBL] [Abstract][Full Text] [Related]
25. Association of Tumor Necrosis Like factor 1 A (TL1A) and its Decoy Receptor (DcR3) with The Disease Activity and Autoantibody Production in Rheumatoid Arthritis Patients.
Soliman MH; Ebaid AM
Egypt J Immunol; 2019 Jan; 26(1):43-54. PubMed ID: 31332995
[TBL] [Abstract][Full Text] [Related]
26. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.
Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M
Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752
[TBL] [Abstract][Full Text] [Related]
27. Decoy strategies: the structure of TL1A:DcR3 complex.
Zhan C; Patskovsky Y; Yan Q; Li Z; Ramagopal U; Cheng H; Brenowitz M; Hui X; Nathenson SG; Almo SC
Structure; 2011 Feb; 19(2):162-71. PubMed ID: 21300286
[TBL] [Abstract][Full Text] [Related]
28. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions.
Hsieh SL; Lin WW
J Biomed Sci; 2017 Jun; 24(1):39. PubMed ID: 28629361
[TBL] [Abstract][Full Text] [Related]
29. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
Lin WW; Hsieh SL
Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Kumanishi S; Yamanegi K; Nishiura H; Fujihara Y; Kobayashi K; Nakasho K; Futani H; Yoshiya S
Int J Oncol; 2019 Jul; 55(1):167-178. PubMed ID: 31180533
[TBL] [Abstract][Full Text] [Related]
31. Interleukin‑12B is upregulated by decoy receptor 3 in rheumatoid synovial fibroblasts.
Fukuda K; Miura Y; Maeda T; Hayashi S; Kurosaka M
Mol Med Rep; 2016 Apr; 13(4):3647-52. PubMed ID: 26956410
[TBL] [Abstract][Full Text] [Related]
32. DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis.
Hayashi S; Nishiyama T; Miura Y; Fujishiro T; Kanzaki N; Hashimoto S; Matsumoto T; Kurosaka M; Kuroda R
Osteoarthritis Cartilage; 2011 Jul; 19(7):903-10. PubMed ID: 21420502
[TBL] [Abstract][Full Text] [Related]
33. Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.
Liu W; Ramagopal U; Cheng H; Bonanno JB; Toro R; Bhosle R; Zhan C; Almo SC
Structure; 2016 Nov; 24(11):2016-2023. PubMed ID: 27806260
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication.
Wu SF; Liu TM; Lin YC; Sytwu HK; Juan HF; Chen ST; Shen KL; Hsi SC; Hsieh SL
J Leukoc Biol; 2004 Feb; 75(2):293-306. PubMed ID: 14634066
[TBL] [Abstract][Full Text] [Related]
35. Modulation of dendritic cell differentiation and maturation by decoy receptor 3.
Hsu TL; Chang YC; Chen SJ; Liu YJ; Chiu AW; Chio CC; Chen L; Hsieh SL
J Immunol; 2002 May; 168(10):4846-53. PubMed ID: 11994433
[TBL] [Abstract][Full Text] [Related]
36. DcR3 protects islet beta cells from apoptosis through modulating Adcyap1 and Bank1 expression.
Han B; Wu J
J Immunol; 2009 Dec; 183(12):8157-66. PubMed ID: 20007581
[TBL] [Abstract][Full Text] [Related]
37. [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof].
Shen HW; Wu YL; Peng SY
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):744-7. PubMed ID: 12899749
[TBL] [Abstract][Full Text] [Related]
38. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.
Roth W; Isenmann S; Nakamura M; Platten M; Wick W; Kleihues P; Bähr M; Ohgaki H; Ashkenazi A; Weller M
Cancer Res; 2001 Mar; 61(6):2759-65. PubMed ID: 11289159
[TBL] [Abstract][Full Text] [Related]
39. Quantification and detection of DcR3, a decoy receptor in TNFR family.
Chen J; Zhang L; Kim S
J Immunol Methods; 2004 Feb; 285(1):63-70. PubMed ID: 14871535
[TBL] [Abstract][Full Text] [Related]
40. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
Ho CH; Chen CL; Li WY; Chen CJ
Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
